Amicus Therapeutics (FOLD) News Today → He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (From InvestorPlace) (Ad) Free fold Stock Alerts $9.57 +0.07 (+0.74%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 7:24 AM | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by BNP Paribas Financial MarketsBNP Paribas Financial Markets boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 138.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 923,045 shares of the biopharmaceutical company's stock after purchasing an additionMay 16 at 4:28 AM | americanbankingnews.comAmicus Therapeutics (NASDAQ:FOLD) Stock Rating Upgraded by GuggenheimMay 15 at 3:36 PM | marketbeat.comM&G Investment Management Ltd. Takes $9.95 Million Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)M&G Investment Management Ltd. acquired a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 710,557 shares of the biopharmMay 14, 2024 | msn.comGuggenheim Upgrades Amicus Therapeutics (FOLD)May 14, 2024 | markets.businessinsider.comEvaluating Amicus Therapeutics: Insights From 6 Financial AnalystsMay 14, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Up to $9.04Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Up to $9.04May 14, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Upgraded by Guggenheim to "Buy"Guggenheim upgraded Amicus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target for the company in a report on Tuesday.May 14, 2024 | americanbankingnews.comAmicus Therapeutics (NASDAQ:FOLD) Given New $19.00 Price Target at Morgan StanleyMay 14, 2024 | americanbankingnews.comNeedham & Company LLC Reiterates "Hold" Rating for Amicus Therapeutics (NASDAQ:FOLD)May 14, 2024 | americanbankingnews.comBank of America Cuts Amicus Therapeutics (NASDAQ:FOLD) Price Target to $13.00May 13, 2024 | americanbankingnews.comAnalysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Price Target at $20.00May 12, 2024 | americanbankingnews.comUBS Group Lowers Amicus Therapeutics (NASDAQ:FOLD) Price Target to $19.00May 10, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Issues Earnings ResultsAmicus Therapeutics (NASDAQ:FOLD - Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.04. The business had revenue of $110.40 million during the quarter, compared to the consensus estimate of $111.19 million. Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. Amicus Therapeutics's quarterly revenue was up 27.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.18) earnings per share.May 10, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) PT Lowered to $19.00 at UBS GroupUBS Group cut their target price on Amicus Therapeutics from $20.00 to $19.00 and set a "buy" rating for the company in a research report on Friday.May 10, 2024 | finance.yahoo.comAmicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects ...May 10, 2024 | finance.yahoo.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call TranscriptMay 10, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Stock Rating Reaffirmed by Needham & Company LLCNeedham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research note on Friday.May 10, 2024 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Rating of "Buy" from BrokeragesAmicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has earned an average recommendation of "Buy" from the three research firms that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a buy rating. The average twelve-monthMay 9, 2024 | investorplace.comFOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Sets New 52-Week Low at $9.30Amicus Therapeutics (NASDAQ:FOLD) Hits New 1-Year Low at $9.30May 9, 2024 | washingtonpost.comAmicus Therapeutics: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comAmicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate UpdatesMay 9, 2024 | marketbeat.comVictory Capital Management Inc. Cuts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Victory Capital Management Inc. cut its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 40.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,752,687 shMay 8, 2024 | globenewswire.comAmicus Therapeutics to Present at the Bank of America 2024 Health Care ConferenceMay 8, 2024 | americanbankingnews.comAmicus Therapeutics (FOLD) Scheduled to Post Quarterly Earnings on ThursdayMay 8, 2024 | barrons.comAmicus Therapeutics Inc.May 4, 2024 | insidertrades.comInsider Selling: Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Sells 7,500 Shares of StockMay 2, 2024 | marketbeat.comAmicus Therapeutics (FOLD) to Release Quarterly Earnings on ThursdayAmicus Therapeutics (NASDAQ:FOLD) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.May 1, 2024 | globenewswire.comAmicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024April 21, 2024 | marketbeat.comVontobel Holding Ltd. Purchases New Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Vontobel Holding Ltd. purchased a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 82,672 shares of the biopharmaceutical company's stock, valued at approximately $1,173,000.April 14, 2024 | nasdaq.comAmicus Therapeutics Becomes Oversold (FOLD)April 10, 2024 | marketbeat.comPeregrine Capital Management LLC Reduces Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Peregrine Capital Management LLC reduced its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 16.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 605,348 shares of the biopharmaceutical company'sMarch 30, 2024 | msn.comNevada’s Lee joins on to Amicus Brief in SCOTUS abortion caseMarch 29, 2024 | msn.comNevada’s Lee, Cortez Masto join on to Amicus Brief in SCOTUS abortion caseMarch 28, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Stock Price Down 2.5%Amicus Therapeutics (NASDAQ:FOLD) Trading Down 2.5%March 27, 2024 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Vanguard Group Inc.Vanguard Group Inc. lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 0.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,131,873 shares of the biopharmaceuticalMarch 22, 2024 | marketbeat.comZacks Research Comments on Amicus Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:FOLD)Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Zacks Research boosted their Q1 2024 earnings per share estimates for Amicus Therapeutics in a report released on Wednesday, March 20th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earningsMarch 21, 2024 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) to Post Q3 2024 Earnings of $0.01 Per Share, Zacks Research ForecastsAmicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Stock analysts at Zacks Research issued their Q3 2024 EPS estimates for shares of Amicus Therapeutics in a research report issued on Wednesday, March 20th. Zacks Research analyst R. Department expects that the biopharmaceutical company willMarch 20, 2024 | marketbeat.comAmicus Therapeutics Target of Unusually High Options Trading (NASDAQ:FOLD)Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) saw some unusual options trading on Wednesday. Stock traders acquired 10,103 call options on the company. This is an increase of approximately 1,275% compared to the typical volume of 735 call options.March 20, 2024 | globenewswire.comAmicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) ReportMarch 18, 2024 | marketbeat.comJPMorgan Chase & Co. Trims Amicus Therapeutics (NASDAQ:FOLD) Target Price to $19.00JPMorgan Chase & Co. cut their price target on shares of Amicus Therapeutics from $21.00 to $19.00 and set an "overweight" rating on the stock in a report on Monday.March 18, 2024 | marketbeat.comWellington Management Group LLP Sells 296,607 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Wellington Management Group LLP reduced its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 3.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,523,689 shares of thMarch 17, 2024 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by American Century Companies Inc.American Century Companies Inc. lifted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 11.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,343,870 shares of the biopharmaceutical company's sMarch 16, 2024 | ca.finance.yahoo.comFOLD Jul 2024 12.000 callMarch 16, 2024 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Sees Significant Growth in Short InterestAmicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) was the recipient of a significant increase in short interest during the month of February. As of February 29th, there was short interest totalling 30,910,000 shares, an increase of 15.4% from the February 14th total of 26,780,000 shares. Based on an average daily trading volume, of 3,280,000 shares, the short-interest ratio is currently 9.4 days.March 16, 2024 | insidertrades.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Director Sells $100,500.00 in StockMarch 12, 2024 | marketbeat.comJPMorgan Chase & Co. Sells 432,962 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)JPMorgan Chase & Co. lessened its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 3.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,009,429 shares of the biopharmaceutical company's sMarch 8, 2024 | marketbeat.comEnvestnet Asset Management Inc. Purchases 248,220 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Envestnet Asset Management Inc. lifted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 170.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 393,728 shares of the biopharmaceutical company's stock after purchasing anMarch 7, 2024 | finance.yahoo.comFOLD Oct 2024 12.000 callMarch 7, 2024 | finance.yahoo.comFOLD Jan 2025 12.000 put Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (Ad)For over four decades, Louis Navellier has found the very best tech stocks... Before the rest of the market. Click for his six specific AI stock in the crosshairs FOLD Media Mentions By Week FOLD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FOLD News Sentiment▼0.350.50▲Average Medical News Sentiment FOLD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FOLD Articles This Week▼134▲FOLD Articles Average Week Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GERN News LGND News DVAX News PRGO News ALKS News MNKD News IRWD News MDGL News INVA News OPK News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FOLD) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders Alliance[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
